Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
CRYPTO
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
TECHNOLOGY
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
INVESTING
Heat Biologics Takes Beating After Pricing $12 Million Stock Offering
By Rob Lenihan
Nov 21, 2018 3:21 PM EST
PRESS RELEASES
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By PR Newswire
Apr 2, 2021 4:05 PM EDT
PRESS RELEASES
Akebia Submits New Drug Application (NDA) To The FDA For Vadadustat For The Treatment Of Anemia Due To Chronic Kidney Disease In Adult Patients On Dialysis And Not On Dialysis
By PR Newswire
Mar 30, 2021 6:00 AM EDT
PRESS RELEASES
Akebia Therapeutics Announces Poster Presentations And Educational Symposium At National Kidney Foundation 2021 Virtual Spring Clinical Meetings
By PR Newswire
Mar 25, 2021 8:00 AM EDT
PRESS RELEASES
Akebia Therapeutics Announces Approval For Additional Indication Of Riona® (ferric Citrate Hydrate) For The Treatment Of Iron Deficiency Anemia In Adult Patients In Japan
By PR Newswire
Mar 24, 2021 8:00 AM EDT
PRESS RELEASES
Akebia Therapeutics Celebrates World Kidney Day And National Kidney Month
By PR Newswire
Mar 11, 2021 8:00 AM EST
PRESS RELEASES
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By PR Newswire
Mar 2, 2021 4:05 PM EST
PRESS RELEASES
Akebia Therapeutics To Present At H.C. Wainwright Global Life Sciences Conference
By PR Newswire
Mar 2, 2021 8:00 AM EST
PRESS RELEASES
Akebia Therapeutics Appoints LeAnne M. Zumwalt, Dialysis Industry Leader, To Board Of Directors
By PR Newswire
Feb 18, 2021 8:00 AM EST
PRESS RELEASES
Akebia Therapeutics To Report Fourth Quarter And Full-Year 2020 Financial Results And Discuss Recent Business Highlights
By PR Newswire
Feb 8, 2021 8:00 AM EST
PRESS RELEASES
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By PR Newswire
Feb 2, 2021 4:05 PM EST
PRESS RELEASES
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By PR Newswire
Jan 5, 2021 4:05 PM EST
PRESS RELEASES
Akebia Therapeutics To Present At 39th Annual J.P. Morgan Healthcare Conference
By PR Newswire
Jan 4, 2021 8:00 AM EST
PRESS RELEASES
AkebiaShares Program: Current Approaches For Managing Hyperphosphatemia And Caring For Patients Via Telehealth
By PR Newswire
Dec 9, 2020 8:00 AM EST
PRESS RELEASES
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By PR Newswire
Dec 2, 2020 4:05 PM EST
PRESS RELEASES
Akebia Therapeutics To Participate In Piper Sandler 32nd Annual Virtual Healthcare Conference
By PR Newswire
Nov 24, 2020 8:00 AM EST
PRESS RELEASES
Akebia Therapeutics Ranked 10th Fastest-Growing Company In North America On Deloitte's 2020 Technology Fast 500™
By PR Newswire
Nov 18, 2020 9:37 AM EST
PRESS RELEASES
Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design And Baseline Characteristics Published In Peer-Reviewed Medical Journal
By PR Newswire
Nov 16, 2020 8:30 AM EST
PRESS RELEASES
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By PR Newswire
Nov 3, 2020 4:05 PM EST
PRESS RELEASES
Akebia Therapeutics To Report Third Quarter 2020 Financial Results And Discuss Recent Business Highlights
By PR Newswire
Oct 26, 2020 8:00 AM EDT
PRESS RELEASES
Akebia Presents Results From Its INNO2VATE Global Phase 3 Program; Demonstrated Efficacy And Cardiovascular Safety Of Vadadustat For The Treatment Of Anemia Due To Chronic Kidney Disease In Adult Patients On Dialysis
By PR Newswire
Oct 22, 2020 5:05 PM EDT
PRESS RELEASES
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By PR Newswire
Oct 2, 2020 4:05 PM EDT
PRESS RELEASES
Akebia Therapeutics Announces September 2020 Investor Conference Schedule
By PR Newswire
Sep 8, 2020 8:00 AM EDT
PRESS RELEASES
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By PR Newswire
Sep 2, 2020 4:05 PM EDT
PRESS RELEASES
Akebia Therapeutics Announces First Commercial Launch Of VAFSEO™ (vadadustat Tablets), A New Oral Treatment For Anemia Due To Chronic Kidney Disease, In Japan
By PR Newswire
Aug 26, 2020 8:00 AM EDT
